| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8632304 | Journal of Diabetes and its Complications | 2018 | 22 Pages |
Abstract
Empagliflozin may be cost-effective compared to standard treatment in T2D patients at high cardiovascular risk.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Elaine Nguyen, Craig I. Coleman, Suresh Nair, Erin R. Weeda,